Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) will release its first quarter 2021 financial results on May 10, 2021, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss these results and provide an update on its DNA Medicines Platform, including ongoing COVID-19 vaccine developments. INOVIO's VGX-3100 has achieved efficacy endpoints in a Phase 3 trial for treating precancerous cervical dysplasia, marking a significant achievement in DNA medicine.
INOVIO (NASDAQ:INO) announced it will transition to a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800, due to the changing landscape of COVID-19 vaccinations. The Department of Defense will discontinue funding for the Phase 3 segment of the INNOVATE trial but will continue funding the ongoing Phase 2 segment. This decision does not reflect the vaccine's data or INOVIO’s performance. INOVIO is also evaluating its pan-COVID variant vaccine, INO-4802, and remains committed to addressing pandemic and endemic vaccine needs.
INOVIO (NASDAQ: INO) has released promising results from a study on its COVID-19 vaccine candidate, INO-4800. The study indicates that INO-4800 generates a robust T cell response against all tested SARS-CoV-2 variants. Additionally, neutralizing activity against the UK and Brazilian variants is comparable to the original strain. INOVIO plans to report Phase 2 results in Q2 and move to Phase 3 shortly after. The vaccine's stability at room temperature and potential for multiple boosts highlight its significance in pandemic management.
INOVIO (NASDAQ:INO) has appointed Michael Cordera as Executive Vice President and General Counsel, effective March 15, 2021. Reporting directly to CEO Dr. J. Joseph Kim, Cordera will oversee the legal team's strategy. He brings extensive life sciences experience from his previous role at Eagle Pharmaceuticals and has held various legal positions internationally. This leadership change comes as INOVIO advances its development of DNA medicines targeting infectious diseases and cancer, with 15 clinical programs currently underway.
INOVIO (NASDAQ: INO) announced that Dr. Joseph Kim and management will present at two investor conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, with virtual 1x1 meetings only. The second is the Oppenheimer 31st Annual Healthcare Conference on March 18 at 10:40 a.m. ET, featuring a corporate presentation. INOVIO is advancing DNA medicines for infectious diseases and cancer, with 15 clinical programs supported by significant partnerships.
Geneos Therapeutics announced the closure of its Series A1 financing round, raising $12 million. The funding, led by Korea Investment Partners, will be used to expand the GT-30 clinical trial for the GNOS-PV02 personalized cancer vaccine targeting hepatocellular carcinoma. The trial's patient enrollment has increased from 12 to 24. The investment indicates strong confidence in Geneos' GT-EPIC platform, designed for individualized cancer treatments. Additionally, Geneos has expanded its leadership team, enhancing its capacity for biopharmaceutical development.
INOVIO (NASDAQ: INO) reported Q4 2020 revenue of $5.6 million, up from $279,000 YoY, with a net loss of $24.3 million, compared to $37.7 million in Q4 2019. The company achieved efficacy endpoints in the Phase 3 REVEAL 1 trial for VGX-3100 and completed enrollment for the Phase 2/3 INNOVATE COVID-19 vaccine trial. Additionally, INOVIO entered a collaboration for INO-4800 in Greater China, potentially receiving up to $108 million. They are also developing next-gen COVID vaccines addressing emerging variants.
INOVIO (NASDAQ: INO) announced positive results from the REVEAL 1 Phase 3 trial for its DNA-based immunotherapy VGX-3100, targeting HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL). The trial achieved statistical significance for the primary endpoint, with a 23.7% response rate in the treatment group compared to 11.3% in the placebo group (p=0.022). All secondary endpoints were also met. There were no serious treatment-related adverse events. INOVIO plans to continue development and follow subjects for safety over 18 months.
INOVIO Pharmaceuticals (NASDAQ: INO) and QIAGEN (NYSE: QGEN) have extended their partnership to develop liquid biopsy-based companion diagnostics utilizing next-generation sequencing (NGS) technology. This collaboration focuses on a diagnostic test to identify women likely to benefit from INOVIO's VGX-3100, an immunotherapy for advanced cervical dysplasia linked to HPV. VGX-3100 is currently undergoing two Phase 3 trials, aiming to be the first non-surgical treatment for this condition. QIAGEN's expertise in bioinformatics will enhance the predictive capability of the diagnostic test.
QIAGEN and INOVIO Pharmaceuticals have extended their partnership with a master collaboration agreement to develop liquid biopsy-based diagnostic products utilizing next-generation sequencing (NGS) technology. The initial project will focus on a diagnostic test for identifying women who may benefit from VGX-3100, INOVIO's immunotherapy for advanced cervical dysplasia linked to HPV. This test will leverage QIAGEN’s bioinformatics to enhance INOVIO’s biomarker signature and will be developed for the Illumina NextSeq 550Dx platform, following a partnership established in 2019.